Histone acetylation and deacetylation
Histone acetylation and deacetylation are the processes by which the lysine residues within the N-terminal tail protruding from the histone core of the nucleosome are acetylated and deacetylated as part of gene regulation.
Histone acetylation and deacetylation are essential parts of gene regulation. These reactions are typically catalysed by enzymes with "histone acetyltransferase" (HAT) or "histone deacetylase" (HDAC) activity. Acetylation is the process where an acetyl functional group is transferred from one molecule (in this case, Acetyl-Coenzyme A) to another. Deacetylation is simply the reverse reaction where an acetyl group is removed from a molecule.
Acetylated histones, octameric proteins that organize chromatin into nucleosomes and ultimately higher order structures, represent a type of epigenetic marker within chromatin. Acetylation removes the positive charge on the histones, thereby decreasing the interaction of the N termini of histones with the negatively charged phosphate groups of DNA. As a consequence, the condensed chromatin is transformed into a more relaxed structure that is associated with greater levels of gene transcription. This relaxation can be reversed by HDAC activity. Relaxed, transcriptionally active DNA is referred to as euchromatin. More condensed (tightly packed) DNA is referred to as heterochromatin. Condensation can be brought about by processes including deacetylation and methylation; the action of methylation is indirect and has no effect upon charge.
- 1 Mechanism of action
- 2 Histone acetylation/deacetylation enzymes
- 2.1 Histone acetyltransferase (HATs)
- 2.2 Histone deacetylase (HDACs)
- 3 Biological functions
- 4 Human diseases
- 5 See also
- 6 References
- 7 External links
Mechanism of action
Nucleosomes are portions of double-stranded DNA (dsDNA) that are wrapped around protein complexes called histone cores. These histone cores are composed of 8 subunits, two each of H2A, H2B, H3 and H4 histones. This protein complex forms a cylindrical shape that dsDNA wraps around with approximately 147 base pairs. Nucleosomes are formed as a beginning step for DNA compaction that also contributes to structural support as well as serves functional roles. These functional roles are contributed by the tails of the histone subunits. The histone tails insert themselves in the minor grooves of the DNA and extend through the double helix, which leaves them open for modifications involved in transcriptional activation. Acetylation has been closely associated with increases in transcriptional activation while deacetylation has been linked with transcriptional deactivation. These reactions occur post-translation and are reversible.
The mechanism for acetylation and deacetylation takes place on the NH3+ groups of Lysine amino acid residues. These residues are located on the tails of histones that make up the nucleosome of packaged dsDNA. The process is aided by factors known as Histone Acetyltransferases (HATs). HAT molecules facilitate the transfer of an acetyl group from a molecule of Acetyl Coenzyme-A (Acetyl-CoA) to the NH3+ group on Lysine. When a Lysine is deacetylated, factors known as Histone Deacetylases (HDACs) catalyze the removal of the acetyl group with a molecule of H2O.
Acetylation has the effect of changing the overall charge of the histone tail from positive to neutral. Nucleosome formation is dependent on the positive charges of the H4 histones and the negative charge on the surface of H2A histone fold domains. Acetylation of the histone tails disrupts this association, leading to weaker binding of the nucleosomal components. By doing this, the DNA is more accessible and leads to more transcription factors being able to reach the DNA. Thus, acetylation of histones is known to increase the expression of genes through transcription activation. Deacetylation performed by HDAC molecules has the opposite effect. By deacetylating the histone tails, the DNA becomes more tightly wrapped around the histone cores, making it harder for transcription factors to bind to the DNA. This leads to decreased levels of gene expression and is known as gene silencing.
Acetylated histones, the octomeric protein cores of nucleosomes, represent a type of epigenetic marker within chromatin. Studies have shown that one modification has the tendency to influence whether another modification will take place. Modifications of histones can not only cause secondary structural changes at their specific points, but can cause many structural changes in distant locations which inevitably effects function. As the chromosome is replicated, the modifications that exist on the parental chromosomes are handed down to daughter chromosomes. The modifications, as part of their function, can recruit enzymes for their particular function and can contribute to the continuation of modifications and their effects after replication has taken place. It has been shown that, even past one replication, expression of genes may still be effected many cell generations later. A study showed that, upon inhibition of HDAC enzymes by Trichostatin A, genes inserted next to centric heterochromatin showed increased expression. Many cell generations later, in the absence of the inhibitor, the increased gene expression was still expressed, showing modifications can be carried through many replication processes such as mitosis and meiosis.
Histone acetylation/deacetylation enzymes
Histone acetyltransferase (HATs)
Histone Acetyltransferases, also known as HATs, are a family of enzymes that acetylate the histone tails of the nucleosome. This, and other modifications, is expressed based on the varying states of the cellular environment. Many proteins with acetylating abilities have been documented and, after a time, were categorized based on sequence similarities between them. These similarities are high among members of a family, but members from different families show very little resemblance. Some of the major families identified so far are as follows.
General Control Non-Derepressible 5 (Gcn5) –related N-Acetyltransferases (GNATs) is one of the many studied families with acetylation abilities. This superfamily includes the factors Gcn5 which is included in the SAGA, SLIK, STAGA, ADA, and A2 complexes, Gcn5L, p300/CREB-binding protein associated factor (PCAF), Elp3, HPA2 and HAT1. Major features of the GNAT family include HAT domains approximately 160 residues in length and a conserved bromodomain that has been found to be an acetyl-lysine targeting motif. Gcn5 has been shown to acetylate substrates when it is part of a complex. Recombinant Gcn5 has been found to be involved in the acetylation of the H3 histones of the nucleosome. To a lesser extent, it has been found to also acetylate H2B and H4 histones when involved with other complexes. PCAF has the ability to act as a HAT protein and acetylate histones, it can acetylate non-histone proteins related to transcription, as well as act as a coactivator in many processes including myogenesis, nuclear-receptor-mediated activation and growth-factor-signaled activation. Elp3 has the ability to acetylate all histone subunits and also shows involvement in the RNA polymerase II holoenzyme.
MOZ (Monocytic Leukemia Zinc Finger Protein), Ybf2/Sas3, Sas2 and Tip60 (Tat Interacting Protein) all make up MYST, another well known family that exhibits acetylating capabilities. This family includes Sas3, essential SAS-related acetyltransferase (Esa1), Sas2, Tip60, MOF, MOZ, MORF, and HBO1. The members of this family have multiple functions, not only with activating and silencing genes, but also effect development and have implications in human diseases. Sas2 and Sas3 are involved in transcription silencing, MOZ and TIF2 are involved with the formation of leukemic transclocation products while MOF is involved in dosage compensation in Drosophila. HAT domains for this family are approximately 250 residues which include cysteine-rich, zinc binding domains as well as N-terminal chromodomains. The MYST proteins Esa1, Sas2 and Sas3 are found in yeast, MOF is found in Drosophila while Tip60, MOZ, MORF, and HBO1 are found in humans. Tip60 has roles in the regulation of gene transcription, HBO has been found to impact the DNA replication process, MORF is able to acetylate free histones (especially H3 and H4) as well as nucleosomal histones.
Adenoviral E1A-associated protein of 300kDa (p300) and the CREB-binding protein (CBP) make up the next family of HATs. This family of HATs contain HAT domains that are approximately 500 residues long and contain bromodomains as well as three cysteine-histidine rich domains that help with protein interactions. These HATs are known to acetylate all of the histone subunits in the nucleosome. They also have the ability to acetylate and mediate non-histone proteins involved in transcription and are also involved in the cell-cycle, differentiation and apoptosis.
There are other proteins that have acetylating abilities but differ in structure to the previously mentioned families. One HAT is called steroid receptor coactivator 1 (SRC1), which has a HAT domain located at the C-terminus end of the protein along with a basic helix-loop-helix and PAS A and PAS B domains with a LXXLL receptor interacting motif in the middle. Another is ATF-2 which contains a transcriptional activation (ACT) domain and a basic zipper DNA-binding (bZip) domain with a HAT domain in-between. The last is TAFII250 which has a Kinase domain at the N-terminus region, two bromodomains located at the C-terminus region and a HAT domain located in-between.
Histone deacetylase (HDACs)
There are a total of four classes that categorize Histone Deacetylases (HDACs). Class I includes HDACs 1, 2, 3, and 8. Class II is divided into two subgroups, Class IIA and Class IIB. Class IIA includes HDACs 4, 5, 7, and 9 while Class IIB includes HDACs 6 and 10. Class III contains the Sirtuins and Class IV contains only HDAC11. Classes of HDAC proteins are divided and grouped together based on the comparison to the sequence homologies of Rpd3, Hos1 and Hos2 for Class I HDACs, HDA1 and Hos3 for the Class II HDACs and the sirtuins for Class III HDACs.
Class I HDACs
HDAC1 & HDAC2
HDAC1 & HDAC2 are in the first class of HDACs are most closely related to one another. By analyzing the overall sequences of both HDACs, their similarity was found to be approximately 82% homologous. These enzymes have been found to be inactive when isolated which lead to the conclusion that they must be incorporated with cofactors in order to activate their deacetylase abilities. There are three major protein complexes that HDAC 1 & 2 may incorporate themselves into. These complexes include Sin3 (named after its characteristic protein mSin3A), Nucleosome Remodelling and Deacetylating complex (NuRD), and Co-REST. The Sin3 complex and the NuRD complex both contain HDACs 1 and 2, the Rb-associated protein 48 (RbAp48) and RbAp46 which make up the core of each complex. Other complexes may be needed though in order to initiate the maximum amount of available activity possible. HDACs 1 and 2 can also bind directly to DNA binding proteins such as Yin and Yang 1 (YY1), Rb binding protein 1 and Sp1. HDACs 1 and 2 have been found to express regulatory roles in key cell cycle genes including p21.
Activity of these HDACs can be affected by phosphorylation. An increased amount of phosphorylation (hyperphosphorylation) leads to increased deacetylase activity, but degrades complex formation between HDACs 1 and 2 and between HDAC1 and mSin3A/YY1. A lower than normal amount of phosphorylation (hypophosphorylation) leads to a decrease in the amount of deacetylase activity, but increases the amount of complex formation. Mutation studies found that major phosphorylation happens at residues Ser421 and Ser423. Indeed, when these residues were mutated, a drastic reduction was seen in the amount of deacetylation activity. This difference in the state of phosphorylation is a way of keeping an optimal level of phosphorylation to ensure there is no over or under expression of deacetylation. HDACs 1 and 2 have been found only exclusively in the nucleus. In HDAC1 knockout (KO) mice, mice were found to die during embryogenesis and showed a drastic reduction in the production but increased expression of Cyclin-Dependent Kinase Inhibitors (CDKIs) p21 and p27. Not even upregulation of the other Class I HDACs could compensate for the loss of HDAC1. This inability to recover from HDAC1 KO leads researchers to believe that there are both functional uniqueness to each HDAC as well as regulatory cross-talk between factors.
HDAC3 has been found to be most closely related to HDAC8. HDAC3 contains a non-conserved region in the C-terminal region that was found to be required for transcriptional repression as well as its deacetylase activity. It also contains two regions, one called a Nuclear Localization Signal (NLS) as well as a Nuclear Export Signal (NES). The NLS functions as a signal for nuclear action while an NES functions with HDACs that perform work outside of the nucleus. A presence of both signals for HDAC3 suggests it travels between the nucleus and the ctyoplasm. HDAC3 has even been found to interact with the plasma membrane. Silencing Mediator for Retinoic Acid and Thyroid Hormone (SMRT) receptors and Nuclear Receptor Co-Repressor (N-CoR) factors must be utilized by HDAC3 in order to activate it. Upon doing so, it gains the ability to co-precipitate with HDACs 4, 5, and 7. HDAC3 can also be found complexed together with HDAC-related protein (HDRP). HDACs 1 and 3 have been found to mediate Rb-RbAp48 interactions which suggests that it functions in cell cycle progression. HDAC3 also shows involvement in stem cell self-renewal and a transcription independent role in mitosis.
HDAC8 has been found to be most similar to HDAC3. Its major feature is its catalytic domain which contains an NLS region in the center. Two transcripts of this HDAC have been found which include a 2.0kb transcript and a 2.4kb transcript. Unlike the other HDAC molecules, when purified, this HDAC showed to be enzymatically active. At this point, due to its recent discovery, it is not yet known if it is regulated by co-repressor protein complexes. Northern blots have revealed that different tissue types show varying degrees of HDAC8 expression but has been observed in smooth muscles and is thought to contribute to contractility.
Class II HDACs
The Class IIA HDACs includes HDAC4, HDAC5, HDAC7 and HDAC9. HDACs 4 and 5 have been found to most closely resemble each other while HDAC7 maintains a resemblance to both of them. There have been three discovered variants of HDAC9 including HDAC9a, HDAC9b and HDAC9c/HDRP, while more have been suspected. The variants of HDAC9 have been found to have similarities to the rest of the Class IIA HDACs. For HDAC9, the splicing variants can be seen as a way of creating a "fine-tuned mechanism" for differentiation expression levels in the cell. Different cell types may take advantage and utilize different isoforms of the HDAC9 enzyme allowing for different forms of regulation. HDACs 4, 5 and 7 have their catalytic domains located in the C-terminus along with an NLS region while HDAC9 has its catalytic domain located in the N-terminus. However, the HDAC9 variant HDAC9c/HDRP lacks a catalytic domain but has a 50% similarity to the N-terminus of HDACs 4 and 5.
For HDACs 4, 5 and 7, conserved binding domains have been discovered that bind for C-terminal binding protein (CtBP), myocyte enhancer factor 2 (MEF2) and 14-3-3. All three HDACs work to repress the myogenic transcription factor MEF2 which an essential role in muscle differentiation as a DNA binding transcription factor. Binding of HDACs to MEF2 inhibits muscle differentiation, which can be reversed by action of Ca2+/calmodulin-dependent kinase (CaMK) which works to dissociate the HDAC/MEF2 complex by phosphorylating the HDAC portion. They have been seen to be involved in cellular hypertrophy in muscle control differentiation as well as cellular hypertrophy in muscle and cartilage tissues. HDACs 5 and 7 have been shown to work in opposition to HDAC4 during muscle differentiation regulation so as to keep a proper level of expression. There has been evidence that these HDACs also interact with HDAC3 as a co-recruitment factor to the SMRT/N-CoR factors in the nucleus. Absence of the HDAC3 enzyme has shown to lead to inactivity which makes researchers believe that HDACs 4, 5 and 7 help the incorporation of DNA-binding recruiters for the HDAC3-containing HDAC complexes located in the nucleus. When HDAC4 is knocked out in mice, they suffer from a pronounced chondrocyte hypertrophy and die due to extreme ossification. HDAC7 has been shown to suppress Nur77-dependent apoptosis. This interaction leads to a role in clonal expansion of T cells. HDAC9 KO mice are shown to suffer from cardiac hypertrophy which is exacerbated in mice that are double KO for HDACs 9 and 5.
The Class IIB HDACs include HDAC6 and HDAC10. These two HDACs are most closely related to each other in overall sequence. However, HDAC6's catalytic domain is most similar to HDAC9. A unique feature of HDAC6 is that it contains two catalytic domains in tandem of one another. Another unique feature of HDAC6 is the HDAC6-, SP3, and Brap2-related zinc finger motif (HUB) domain in the C-terminus which shows some functions related to ubiquitination, meaning this HDAC is prone to degradation. HDAC10 has two catalytic domains as well. One active domain is located in the N-terminus and a putative catalytic domain is located in the C-terminus along with an NES domain. Two putative Rb-binding domains have also been found on HDAC10 which shows it may have roles in the regulation of the cell cycle. Two variants of HDAC10 have been found, both having slight differences in length. HDAC6 is the only HDAC to be shown to act on tubulin, acting as a tubulin deacetylase which helps in the regulation of microtubule-dependent cell motility. It is mostly found in the cytoplasm but has been known to be found in the nucleus, complexed together with HDAC11. HDAC10 has been seen to act on HDACs 1, 2, 3 (or SMRT), 4, 5 and 7. Some evidence has been shown that it may have small interactions with HDAC6 as well. This leads researchers to believe that HDAC10 may function more as a recruiter rather than a factor for deacetylation. However, experiments conducted with HDAC10 did indeed show deacetylation activity.
Class IV HDACs
HDAC11 has been shown to be related to HDACs 3 and 8, but its overall sequence is quite different from the other HDACs, leading it to be in its own category. HDAC11 has a catalytic domain located in its N-terminus. It has not been found incorporated in any HDAC complexes such as Nurd or SMRT which means it may have a special function unique to itself. It has been found that HDAC11 remains mainly in the nucleus.
The discovery of histone acetylation causing changes in transcription activity can be traced back to the work of Vicent Allfrey and colleagues in 1964. The group hypothesized that histone proteins modified by acetyl groups added negative charges to the positive lysines, and thus, reduced the interaction between DNA and histones. Histone modification is now considered a major regulatory mechanism that is involved in many different stages of genetic functions. Our current understanding is that acetylated lysine residues on histone tails is associated with transcriptional activation. In turn, deacetylated histones are associated with transcriptional repression.
The regulatory mechanism is thought to be twofold. Lysine is an amino acid with a positive charge when unmodified. Lysines on the amino terminal tails of histones have a tendency to weaken the chromatin's overall structure. Addition of an acetyl group, which carries a negative charge, effectively removes the positive charge and hence, reduces the interaction between the histone tail and the nucleosome. This opens up the usually tightly packed nucleosome and allows transcription machinery to come into contact with the DNA template, leading to gene transcription. Repression of gene transcription is achieved by the reverse of this mechanism. The acetyl group is removed by one of the HDAC enzymes during deacetylation, allowing histones to interact with DNA more tightly to form compacted nucleosome assembly. This increase in the rigid structure prevents the incorporation of transcriptional machinery, effectively silencing gene transcription.
Another implication of histone acetylation is to provide a platform for protein binding. As a posttranslational modification, the acetylation of histones can attract proteins to elongated chromatin that has been marked by acetyl groups. It has been hypothesized that the histone tails offer recognition sites that attract proteins responsible for transcriptional activation. Unlike histone core proteins, histone tails are not part of the nucleosome core and are exposed to protein interaction. A model proposed that the acetylation of H3 histones activates gene transcription by attracting other transcription related complexes. Therefore, the acetyl mark provides a site for protein recognition where transcription factors interact with the acetylated histone tails via their bromodomain.
Histone code hypothesis
The Histone code hypothesis suggests the idea that patterns of post-translational modifications on histones, collectively, can direct specific cellular functions. Chemical modifications of histone proteins often occur on particular amino acids. This specific addition of single or multiple modifications on histone cores can be interpreted by transcription factors and complexes which leads to functional implications. This process is facilitated by enzymes such as HATs and HDACs that add or remove modifications on histones, and transcription factors that process and "read" the modification codes. The outcome can be activation of transcription or repression of a gene. For example, the combination of acetylation and phosphorylation have synergistic effects on the chromosomes overall structural condensation level and, hence, induces transcription activation of immediate early gene.
Experiments investigating acetylation patterns of H4 histones suggested that these modification patterns are collectively maintained in mitosis and meiosis in order to modify long-term gene expression. The acetylation pattern is regulated by HAT and HADC enzymes and, in turn, sets the local chromatin structure. In this way, acetylation patterns are transmitted and interconnected with protein binding ability and functions in subsequent cell generation.
The bromodomain is a motif that is responsible for acetylated lysine recognition on histones by nucleosome remodelling proteins. Posttranslational modifications of N- and C-terminal histone tails attracts various transcription initiation factors that contain bromodomains, including human transcriptional coactivator PCAF, TAF1, GCN5 and CREB-binding protein(CBP), to the promoter and have a significance in regulating gene expression. Structural analysis of transcription factors has shown that highly conserved bromodomains are essential for protein to bind to acetylated lysine.This suggests that specific histone site acetylation has a regulatory role in gene transcriptional activation.
Gene expression is regulated by histone acetylation and deacetylation, and this regulation is also applicable to inflammatory genes. Inflammatory lung diseases are characterized by expression of specific inflammatory genes such as NF-κB and AP-1 transcription factor. Treatments with corticosteroids and theophylline for inflammatory lung diseases interfere with HAT/HDAC activity to turn off inflammatory genes.
Specifically, gene expression data demonstrated increased activity of HAT and decreased level of HDAC activity in patients with Asthma. Patients with chronic obstructive pulmonary disease showed there is an overall decrease in HDAC activity with unchanged levels of HAT activity. Results have shown that there is an important role for HAT/HDAC activity balance in inflammatory lung diseases and provided insights on possible therapeutic targets.
Due to the regulatory role during transcription of epigenetic modifications in genes, it is not surprising that changes in epigenetic markers, such as acetylation, can contribute to cancer development. HDACs expression and activity in tumor cells is very different from normal cells. The overexpression and increased activity of HDACs has been shown to be characteristic of tumorigenesis and metastasis, suggesting an important regulatory role of histone deacetylation on oncogene expression. One of the examples is the regulation role of histone acetylation/deacetylation in P300 and CBP, both of which contribute to oncogenesis.
Approved in 2006 by the U.S. Food and Drug Administration (FDA), Vorinostat represents a new category for anticancer drugs that are in development. Vorinostat targets histone acetylation mechanisms and can effectively inhibit abnormal chromatin remodeling in cancerous cells. Targets of Vorinostat includes HDAC1, HDAC2, HDAC3 and HDAC6.
Suggested by the idea that the structure of chromatin can be modified to allow or deny access of transcription activators, regulatory functions of histone acetylation and deacetylation can have implications with genes that cause other diseases. Studies on histone modifications may reveal many novel therapeutic targets.
Based on different cardiac hypertrophy models, it is been demonstrated that cardiac stress can result in gene expression changes and alter cardiac function. These changes are mediated through HATs/HDACs posttranslational modification signaling. HDAC inhibitor trichostatin A was reported to reduce stress induced cardiomyocyte autophagy. Studies on p300 and CREB-binding protein linked cardiac hypertrophy with cellular HAT activity suggesting an essential role of histone acetylation status with hypertrophy responsive genes such as GATA4, SRF, and MEF2.
Epigenetic modifications also play a role in neurological disorders. Deregulation of histones modification are found to be responsible for deregulated gene expression and hence associated with neurological and psychological disorders, such as Schizophrenia and Huntington disease. Current studies indicate that inhibitors of the HDAC family have therapeutic benefits in a wide range of neurological and psychiatric disorders. Many neurological disorders only affect specific brain regions, therefore, understanding of the specificity of HDACs is still required for further investigations for improved treatments.
- Histone acetyltransferase
- Histone deacetylase
- Histone methylation
- University, James D. Watson, Cold Spring Harbor Laboratory, Tania A. Baker, Massachusetts Institute of Technology, Alexander Gann, Cold Spring Harbor Laboratory, Michael Levine, University of California, Berkeley, Richard Losik, Harvard (2014). Molecular biology of the gene (Seventh edition ed.). Boston: Pearson/CSH Press. ISBN 978-0-321-76243-6.
- Verdone, L; Agricola, E; Caserta, M; Di Mauro, E (Sep 2006). "Histone acetylation in gene regulation.". Briefings in functional genomics & proteomics 5 (3): 209–21. doi:10.1093/bfgp/ell028. PMID 16877467.
- Kuo, MH; Allis, CD (Aug 1998). "Roles of histone acetyltransferases and deacetylases in gene regulation.". BioEssays : news and reviews in molecular, cellular and developmental biology 20 (8): 615–26. doi:10.1002/(sici)1521-1878(199808)20:8<615::aid-bies4>3.0.co;2-h. PMID 9780836.
- Grunstein, Michael (25 September 1997). "Histone acetylation in chromatin structure and transcription". Nature 389 (6649): 349–352. doi:10.1038/38664. PMID 9311776. Retrieved 7 August 2012.
- de Ruijter, AJ; van Gennip, AH; Caron, HN; Kemp, S; van Kuilenburg, AB (Mar 15, 2003). "Histone deacetylases (HDACs): characterization of the classical HDAC family.". The Biochemical journal 370 (Pt 3): 737–49. doi:10.1042/BJ20021321. PMC 1223209. PMID 12429021. Retrieved 8 April 2014.
- Gallinari, P; Di Marco, S; Jones, P; Pallaoro, M; Steinkühler, C (Mar 2007). "HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.". Cell research 17 (3): 195–211. doi:10.1038/sj.cr.7310149. PMID 17325692.
- Struhl, Kevin (1998). "Histone acetylation and transcriptional regulatory mechanisms". Genes & Dev. 12 (5): 599–606. doi:10.1101/gad.12.5.599. Retrieved 7 August 2012.
- Turner, BM (Sep 2000). "Histone acetylation and an epigenetic code.". BioEssays : news and reviews in molecular, cellular and developmental biology 22 (9): 836–45. doi:10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X. PMID 10944586.
- Marmorstein, R (Aug 17, 2001). "Structure of histone acetyltransferases.". Journal of Molecular Biology 311 (3): 433–44. doi:10.1006/jmbi.2001.4859. PMID 11492997.
- Yang, XJ; Seto, E (Aug 13, 2007). "HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.". Oncogene 26 (37): 5310–8. doi:10.1038/sj.onc.1210599. PMID 17694074.
- Torok, MS; Grant, PA (2004). "Histone acetyltransferase proteins contribute to transcriptional processes at multiple levels.". Advances in protein chemistry 67: 181–99. doi:10.1016/S0065-3233(04)67007-0. PMID 14969728.
- Marmorstein, R; Roth, SY (Apr 2001). "Histone acetyltransferases: function, structure, and catalysis.". Current opinion in genetics & development 11 (2): 155–61. doi:10.1016/S0959-437X(00)00173-8. PMID 11250138.
- Allfrey, VG; Faulkner, R; Mirsky, AE (May 1964). "Acetylation and Methylation of Histones and Their Possible Role in the Regulation of RNA Synthesis.". Proceedings of the National Academy of Sciences of the United States of America 51: 786–94. doi:10.1073/pnas.51.5.786. PMC 300163. PMID 14172992.
- Mukhopadhyay, Rajendrani. "Vincent Allfrey's Work on Histone Acetylation". Journal of Biological Chemistry 287 (3): 2270–2271. doi:10.1074/jbc.O112.000248.
- Zentner, GE; Henikoff, S (Mar 2013). "Regulation of nucleosome dynamics by histone modifications.". Nature structural & molecular biology 20 (3): 259–66. doi:10.1038/nsmb.2470. PMID 23463310.
- Spange, S; Wagner, T; Heinzel, T; Krämer, OH (Jan 2009). "Acetylation of non-histone proteins modulates cellular signalling at multiple levels.". The international journal of biochemistry & cell biology 41 (1): 185–98. doi:10.1016/j.biocel.2008.08.027. PMID 18804549.
- University, James D. Watson, Cold Spring Harbor Laboratory, Tania A. Baker, Massachusetts Institute of Technology, Alexander Gann, Cold Spring Harbor Laboratory, Michael Levine, University of California, Berkeley, Richard Losik, Harvard (2014). Molecular biology of the gene (Seventh edition ed.). Boston: Pearson/CSH Press. p. 242. ISBN 978-0-321-76243-6.
- Cheung, P; Allis, CD; Sassone-Corsi, P (Oct 13, 2000). "Signaling to chromatin through histone modifications.". Cell 103 (2): 263–71. doi:10.1016/s0092-8674(00)00118-5. PMID 11057899.
- Winston, F; Allis, CD (Jul 1999). "The bromodomain: a chromatin-targeting module?". Nature Structural Biology 6 (7): 601–4. doi:10.1038/10640. PMID 10404206.
- Chi, P; Allis, CD; Wang, GG (Jul 2010). "Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers.". Nature reviews. Cancer 10 (7): 457–69. doi:10.1038/nrc2876. PMC 3262678. PMID 20574448. Retrieved 9 April 2014.
- Barratt, MJ; Hazzalin, CA; Cano, E; Mahadevan, LC (May 24, 1994). "Mitogen-stimulated phosphorylation of histone H3 is targeted to a small hyperacetylation-sensitive fraction.". Proceedings of the National Academy of Sciences of the United States of America 91 (11): 4781–5. doi:10.1073/pnas.91.11.4781. PMC 43872. PMID 8197135. Retrieved 22 April 2014.
- Sanchez, Roberto; Ming-Ming Zhou (September 2009). "The role of human bromodomains in chromatin biology and gene transcription". Curr Opin Drug Discov Devel. 12 (5): 659–665. PMC 2921942. PMID 19736624. Retrieved 8 April 2014.
- Filippakopoulos, Panagis; Knapp, Stefan. "Targeting bromodomains: epigenetic readers of lysine acetylation". Nature Reviews Drug Discovery 13 (5): 337–356. doi:10.1038/nrd4286.
- Barnes, PJ; Adcock, IM; Ito, K (Mar 2005). "Histone acetylation and deacetylation: importance in inflammatory lung diseases.". The European respiratory journal 25 (3): 552–63. doi:10.1183/09031936.05.00117504. PMID 15738302.
- Kuo, CH; Hsieh, CC; Lee, MS; Chang, KT; Kuo, HF; Hung, CH (Jan 2014). "Epigenetic regulation in allergic diseases and related studies.". Asia Pacific allergy 4 (1): 14–8. doi:10.5415/apallergy.2014.4.1.14. PMC 3921865. PMID 24527405. Retrieved 6 May 2014.
- Mroz, RM; Noparlik, J; Chyczewska, E; Braszko, JJ; Holownia, A (Nov 2007). "Molecular basis of chronic inflammation in lung diseases: new therapeutic approach.". Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 58 Suppl 5 (Pt 2): 453–60. PMID 18204158.
- Barnes, P. J. (March 2005). "Histone acetylation and deacetylation: importance in inflammatory lung diseases". European Respiratory Journal 25 (3): 552–563. doi:10.1183/09031936.05.00117504. PMID 15738302.
- Glozak, MA; Seto, E (Aug 13, 2007). "Histone deacetylases and cancer.". Oncogene 26 (37): 5420–32. doi:10.1038/sj.onc.1210610. PMID 17694083.
- Cohen, I.; Poreba, E.; Kamieniarz, K.; Schneider, R. (19 August 2011). "Histone Modifiers in Cancer: Friends or Foes?". Genes & Cancer 2 (6): 631–647. doi:10.1177/1947601911417176.
- Duvic, M; Talpur, R; Ni, X; Zhang, C; Hazarika, P; Kelly, C; Chiao, JH; Reilly, JF; Ricker, JL; Richon, VM; Frankel, SR (Jan 1, 2007). "Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).". Blood 109 (1): 31–9. doi:10.1182/blood-2006-06-025999. PMC 1785068. PMID 16960145. Retrieved 21 April 2014.
- Grant, Steven; Chris Easley (January 2007). "Vorinostat". Nature Reviews Drug Discovery 6: 21–22. doi:10.1038/nrd2227.
- Mano, H (Jan 2008). "Epigenetic abnormalities in cardiac hypertrophy and heart failure.". Environmental health and preventive medicine 13 (1): 25–9. doi:10.1007/s12199-007-0007-8. PMC 2698246. PMID 19568876. Retrieved 22 April 2014.
- Cao, DJ; Wang, ZV; Battiprolu, PK; Jiang, N; Morales, CR; Kong, Y; Rothermel, BA; Gillette, TG; Hill, JA (Mar 8, 2011). "Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy.". Proceedings of the National Academy of Sciences of the United States of America 108 (10): 4123–8. doi:10.1073/pnas.1015081108. PMC 3053983. PMID 21367693. Retrieved 22 April 2014.
- Zhang, CL; McKinsey, TA; Chang, S; Antos, CL; Hill, JA; Olson, EN (Aug 23, 2002). "Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy.". Cell 110 (4): 479–88. doi:10.1016/S0092-8674(02)00861-9. PMID 12202037.
- Lehmann, LH; Worst, BC; Stanmore, DA; Backs, J (May 2014). "Histone deacetylase signaling in cardioprotection.". Cellular and molecular life sciences : CMLS 71 (9): 1673–90. doi:10.1007/s00018-013-1516-9. PMC 3983897. PMID 24310814. Retrieved 6 May 2014.
- Wang, Y; Miao, X; Liu, Y; Li, F; Liu, Q; Sun, J; Cai, L (2014). "Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases.". Oxidative medicine and cellular longevity 2014: 641979. doi:10.1155/2014/641979. PMC 3945289. PMID 24693336. Retrieved 6 May 2014.
- Shikama, N; Lutz, W; Kretzschmar, R; Sauter, N; Roth, JF; Marino, S; Wittwer, J; Scheidweiler, A; Eckner, R (Oct 1, 2003). "Essential function of p300 acetyltransferase activity in heart, lung and small intestine formation.". The EMBO Journal 22 (19): 5175–85. doi:10.1093/emboj/cdg502. PMC 204485. PMID 14517255. Retrieved 22 April 2014.
- Tang, B; B Dean,2,3 and E A Thomas1,* (Dec 2011). "Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders". Transl Psychiatry. e64. (1(12)).
- Lee, J; Hwang, YJ; Kim, KY; Kowall, NW; Ryu, H (Oct 2013). "Epigenetic mechanisms of neurodegeneration in Huntington's disease.". Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 10 (4): 664–76. doi:10.1007/s13311-013-0206-5. PMID 24006238.
- Grayson, DR; Kundakovic, M; Sharma, RP (Feb 2010). "Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?". Molecular Pharmacology 77 (2): 126–35. doi:10.1124/mol.109.061333. PMID 19917878.
- Animation of histone tail acetylation and deacetylation: